Search

Your search keyword '"Reperfusion injury -- Prevention"' showing total 25 results
Start Over Descriptor "Reperfusion injury -- Prevention" Publication Type News
25 results on '"Reperfusion injury -- Prevention"'

1. PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

Subjects
United States. Food and Drug Administration, Transplantation of organs, tissues, etc., Ketamine, Orphan drugs, Reperfusion injury -- Prevention, Banking, finance and accounting industries, Business
Abstract

TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the 'Company' or 'PharmaTher') (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food [...]

Published
2022

3. Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Subjects
United States. Food and Drug Administration, Orphan drugs, Reperfusion injury -- Prevention, Liver -- Transplantation, Industrial research, Research and development, Banking, finance and accounting industries, Business
Abstract

TORONTO, Feb 15, 2022 (GLOBE NEWSWIRE via COMTEX) -- Revive Therapeutics Ltd. ('Revive' or the 'Company') (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research [...]

Published
2022

4. Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

Subjects
United States. Food and Drug Administration, Drug delivery systems, Marijuana, Liver diseases -- Prevention, Reperfusion injury -- Prevention, Organ transplantation, Cannabidiol, Surgery, Ischemia, Liver, Orphan drugs, Novels, General interest, News, opinion and commentary
Abstract

CANADA: Revive Therapeutics Ltd. has issued the following press release: Revive Therapeutics Ltd. ('Revive' and the 'Company') (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for [...]

Published
2020

5. Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

Subjects
Drug delivery systems, Marijuana, Liver diseases -- Prevention, Reperfusion injury -- Prevention, Organ transplantation, Liver, Cannabidiol, Surgery, Ischemia, Orphan drugs, Novels, Business, international, Law
Abstract

(GlobeNewswire) - Revive Therapeutics Ltd. (Revive and the Company) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an [...]

Published
2020

6. Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

Subjects
Drug delivery systems, Marijuana, Liver diseases -- Prevention, Reperfusion injury -- Prevention, Organ transplantation, Liver, Cannabidiol, Surgery, Ischemia, Orphan drugs, Novels, Banking, finance and accounting industries, Business
Abstract

TORONTO, Jan 20, 2020 (GLOBE NEWSWIRE via COMTEX) -- Revive Therapeutics Ltd. ('Revive' and the 'Company') (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare [...]

Published
2020

7. Studies Conducted at Zhengzhou University on Transcription Factors Recently Reported (Alpinetin Protects Against Hepatic Ischemia/reperfusion Injury In Mice By Inhibiting the Nf-kappa B/mapk Signaling Pathways)

Subjects
Reperfusion injury -- Prevention, Protein kinases -- Health aspects, Cellular signal transduction -- Health aspects, Phytochemicals -- Usage -- Health aspects, Liver diseases -- Prevention, Transcription factors -- Health aspects, Biological sciences, Health
Abstract

2021 JUN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish new report on Proteins - Transcription Factors. According to news reporting out [...]

Published
2021

9. New Findings from C.HMD. Santos and Co-Authors Describe Advances in Reperfusion Injury (Effect of Ischemic Postconditioning and Atorvastatin in the Prevention of Remote Lung Reperfusion Injury)

Subjects
Atorvastatin, Reperfusion injury -- Prevention, Antilipemic agents, Lung diseases -- Prevention, Health, Health care industry
Abstract

2018 JUL 1 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Current study results on Cardiovascular Diseases and Conditions - Reperfusion Injury [...]

Published
2018

10. RegeneRx anticipates EU patent for use of TB4 in preventing & treating damage associated with reperfusion injury

Subjects
Patents, Reperfusion injury -- Prevention, Biological products -- Intellectual property, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Apr 07, 2016 (M2 EQUITYBITES via COMTEX) -- Therapeutic peptides company RegeneRx Biopharmaceuticals (Other OTC:RGRX) stated on Wednesday that the European Patent Office (EPO) intends to grant a patent covering [...]

Published
2016

11. RegeneRx anticipates EU patent for use of TI[superscript two]4 in preventing & treating damage associated with reperfusion injury

Subjects
Patents, Reperfusion injury -- Prevention, Biological products -- Intellectual property, Patent/copyright issue, Chemistry
Abstract

M2 PHARMA-April 7, 2016-RegeneRx anticipates EU patent for use of Tβ4 in preventing & treating damage associated with reperfusion injury (C)2016 M2 COMMUNICATIONS Therapeutic peptides company RegeneRx Biopharmaceuticals (Other OTC:RGRX) [...]

Published
2016

12. RegeneRx anticipates EU patent for use of TI[superscript two]4 in preventing & treating damage associated with reperfusion injury

Subjects
Patents, Reperfusion injury -- Prevention, Biological products -- Intellectual property, Patent/copyright issue, Business
Abstract

M2 EQUITYBITES-April 7, 2016-RegeneRx anticipates EU patent for use of Tβ4 in preventing & treating damage associated with reperfusion injury (C)2016 M2 COMMUNICATIONS http://www.m2.com Therapeutic peptides company RegeneRx Biopharmaceuticals (Other [...]

Published
2016

14. Public summary of opinion on orphan designation: recombinant human minibody against complement component C5 fused with RGD-motif for the prevention of the ischaemia/reperfusion injury associated with solid organ transplantation

Subjects
Transplantation of organs, tissues, etc., Reperfusion injury -- Prevention, Orphans, Business, Chemicals, plastics and rubber industries, European Union. European Commission
Abstract

On 20 Jan 2009, orphan designation (EU/3/08/604) was granted by the European Commission to Adienne Srl, Italy, for recombinant human minibody against complement component C5 fused with RGD-motif for the [...]

Published
2010

15. RegeneRx Receives Second $100,000 Award from State of Maryland to Develop Novel Treatment for Cardiac Reperfusion Injury

Subjects
RegeneRx Biopharmaceuticals Inc. -- Intellectual property, Biological products industry -- Intellectual property, Reperfusion injury -- Prevention, Business, Business, international
Abstract

BETHESDA, Md. -- RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that it received a second $100,000 award from the State of Maryland Industrial Partnerships (MIPS) program after successful completion of [...]

Published
2008

16. Reperfusion injury is prevented by bradykinin targeting mitochondrial permeability transition pore

Subjects
University of North Carolina at Chapel Hill, Bradykinin, Reperfusion injury -- Prevention, Glycogen -- Synthesis, Permeability, Health, Science and technology, Prevention
Abstract

Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. According to recent research from the United States, "Although bradykinin has been demonstrated to protect [...]

Published
2006

17. Reperfusion injury is prevented by bradykinin targeting mitochondrial permeability transition pore

Subjects
University of North Carolina at Chapel Hill, Bradykinin, Reperfusion injury -- Prevention, Glycogen -- Synthesis, Permeability, Health, Prevention
Abstract

Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. According to recent research from the United States, "Although bradykinin has been demonstrated to protect [...]

Published
2006

18. Reperfusion injury is prevented by bradykinin targeting mitochondrial permeability transition pore

Subjects
Prevention, Bradykinin, Glycogen synthesis, Reperfusion injury -- Prevention, Permeability, Glycogen, Peptide hormones, Glycogen -- Synthesis
Abstract

Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. According to recent research from the United States, 'Although bradykinin has been demonstrated to protect [...]

Published
2006

19. During ischemia/reperfusion injury, rotigaptide reduces infarct size and prevents arrhythmias

Subjects
Cytology, Anti-arrhythmia drugs, Reperfusion injury -- Prevention, Arrhythmia -- Prevention, Health, Science and technology, Diseases, Prevention
Abstract

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. According to recent research published in the Journal of Pharmacology and Experimental Therapeutics, [...]

Published
2006

20. During ischemia/reperfusion injury, rotigaptide reduces infarct size and prevents arrhythmias

Subjects
Arrhythmia -- Prevention, Reperfusion injury -- Prevention, Cytology, Anti-arrhythmia drugs
Abstract

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. According to recent research published in the Journal of Pharmacology and Experimental Therapeutics, [...]

Published
2006

21. During ischemia/reperfusion injury, rotigaptide reduces infarct size and prevents arrhythmias

Subjects
Cytology, Anti-arrhythmia drugs, Reperfusion injury -- Prevention, Arrhythmia -- Prevention, Health, Diseases, Prevention
Abstract

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. According to recent research published in the Journal of Pharmacology and Experimental Therapeutics, [...]

Published
2006

22. PROTECTIVE EFFECT OF RIBI'S MPL AGAINST REPERFUSION INJURY DEMONSTRATED IN PRECLINICAL DATA PRESENTED AT ASPET MEETING

Subjects
Ribi ImmunoChem Research Inc. -- Product development, Reperfusion injury -- Prevention, Biological products industry -- Product development, Business, News, opinion and commentary
Abstract

PROTECTIVE EFFECT OF RIBI'S MPL AGAINST REPERFUSION INJURY DEMONSTRATED IN PRECLINICAL DATA PRESENTED AT ASPET MEETING HAMILTON, Mont., Sept. 10 /PRNewswire/ -- Important preclinical data presented recently indicate that MPL(R) [...]

Published
1992

23. Nitric Oxide Synthase Gene Transfer Ameliorates Lung Allograft Injury

Subjects
Lungs -- Transplantation, Transplantation of organs, tissues, etc., Reperfusion injury -- Prevention, Health, Prevention
Abstract

2000 APR 23 - (NewsRx.com) -- Adenovirus-mediated endothelial nitric oxide synthase (NOS) gene transfer in vivo reduced ischemia-reperfusion injury in lung allografts, determined recent research from the United States. 'Nitric [...]

Published
2000

24. Hypertonic-Hyperoncotic Volume Substitute Reduces Injury

Subjects
Reperfusion injury -- Prevention, Liver -- Transplantation
Abstract

2000 APR 13 - (NewsRx.com) -- The use of a perioperative hypertonic-hyperoncotic solution for volume substitution was associated with reduced reperfusion injury in an animal study. In liver transplantation ischemia [...]

Published
2000

25. Adprotech Ltd. (Other News To Note)

Subjects
AdProTech Ltd. -- Research, Clinical trials, Pharmaceutical industry -- Research, Reperfusion injury -- Prevention, Biotechnology industry, Business, Business, international
Abstract

* Adprotech Ltd., of Saffron Waldon, UK, announced lead product APT070 has entered Phase IIa clinical trials for the prevention of ischemia reperfusion (I/R) injury in kidney transplants. APT070 reduces [...]

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results